Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Nicolas Girard, MD, PhD, discusses data from the COCOON trial for patients with EGFR-mutant advanced non–small cell lung cancer.

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

“Right now, only 20% of patients with EGFR-positive NSCLC survive beyond five years,” explained Joshua Bauml, vice president, ...

Johnson & Johnson (NYSE: JNJ) has announced important overall survival (OS) results from the Phase III MARIPOSA study.

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) – and now ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Johnson & Johnson (JNJ – Research ...